Invesco S&P MidCap Momentum ETF
XMMO - ETF AI Analysis
Top Page
Invesco S&P MidCap Momentum ETF (XMMO)
XMMO, the Invesco S&P MidCap Momentum ETF, earns a solid overall rating thanks to several strong core holdings with healthy growth and positive outlooks, such as TechnipFMC and ATI, which show robust financial performance and supportive technical trends. United Therapeutics and TD SYNNEX also add strength through solid revenues and strategic initiatives, though names like Roivant Sciences and Jazz Pharmaceuticals, with weaker financial performance and valuation concerns, slightly weigh on the fund. The main risk factor is its focus on mid-cap momentum stocks, which can lead to higher volatility and sensitivity to shifts in market sentiment.
XMMO vs. SPDR S&P 500 ETF (SPY)
- AUM
- 6.39B
- Region
- North America
- Expense Ratio
- 0.34%
- Beta
- 1.02
- Issuer
- Invesco
- Inception Date
- Mar 03, 2005
- Dividend Yield
- 0.73%
- Asset Class
- Equity
- Index Tracked
- S&P MidCap 400 Momentum Index (USD)
XMMO Summary
XMMO is the Invesco S&P MidCap Momentum ETF, which follows the S&P MidCap 400 Momentum Index. It focuses on medium‑sized U.S. companies that have been rising in price, aiming to capture ongoing growth trends. The fund spreads money across many sectors, including technology, industrials, health care, and energy. Well-known names in the ETF include United Therapeutics and TD SYNNEX Corporation. Someone might invest in XMMO to seek growth while diversifying beyond large, well-known stocks. A key risk is that momentum stocks can fall quickly, and the ETF’s value can go up and down with the overall stock market.
How much will it cost me?
This ETF has an expense ratio of 0.34%, which means you’ll pay about $3.40 per year for every $1,000 you invest. That cost is slightly higher than the cheapest index ETFs because it tracks a more specialized momentum strategy rather than a plain-vanilla broad market index.
What would affect this ETF?
This ETF is focused on U.S. mid-sized companies with strong recent stock performance, especially in technology, industrials, health care, and energy, so it could benefit if the U.S. economy stays healthy, business investment grows, and market leaders in these sectors keep doing well. On the other hand, it could be hurt by rising interest rates, an economic slowdown that hits mid-sized companies harder than large ones, or sector-specific setbacks in areas like health care regulation or energy prices that weigh on its top holdings.
XMMO Top 10 Holdings
XMMO is leaning hard into U.S. mid-cap momentum, with a clear tilt toward industrials, energy, and health care rather than the usual Big Tech suspects. TechnipFMC and HF Sinclair have been rising steadily, giving the fund a strong energy engine, while United Therapeutics and Roivant add a healthy dose of biotech momentum. On the flip side, names like MKS Instruments and Jazz Pharmaceuticals have been lagging lately, acting as a bit of a brake. Overall, it’s a domestically focused, sector-diversified bet on mid-cap companies that are currently in motion.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Roivant Sciences | 4.22% | $267.19M | $28.64B | 92.27% | 58Neutral | |
| ATI | 4.19% | $265.13M | $24.87B | 85.77% | 78Outperform | |
| TechnipFMC | 4.25% | $268.84M | $25.76B | 53.52% | 80Outperform | |
| MKS | 2.61% | $165.51M | $14.58B | 49.64% | 75Outperform | |
| Jazz Pharmaceuticals | 2.61% | $165.37M | $15.50B | 70.45% | 64Neutral | |
| United Therapeutics | 2.66% | $168.53M | $25.18B | 27.88% | 79Outperform | |
| HF Sinclair Corporation | 2.57% | $162.98M | $17.51B | 89.12% | 68Neutral | |
| TD SYNNEX Corporation | 2.52% | $159.73M | $18.95B | 57.90% | 73Outperform | |
| BrightSpring Health Services, Inc. | 2.39% | $151.20M | $14.17B | 124.28% | 67Neutral | |
| Lattice Semiconductor | 2.12% | $134.47M | $15.98B | 73.97% | 71Outperform |
XMMO Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XMMO, the sentiment is Negative. The current price of 135.57 is below the 20-day moving average (MA) of 136.31, below the 50-day MA of 143.40, and below the 200-day MA of 153.21, indicating a bearish trend. The MACD of -2.57 indicates Negative momentum. The RSI at 45.02 is Neutral, neither overbought nor oversold. The STOCH value of 84.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XMMO.
XMMO Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $135.57 | $152.00(12.12% Upside) | $6.39B | 0.34% | 71Outperform | |
| $41.91 | $49.30(17.64% Upside) | $8.88B | 0.23% | 69Neutral | |
| $74.06 | $88.26(19.17% Upside) | $6.18B | 0.41% | 70Neutral | |
| $120.09 | $138.38(15.23% Upside) | $5.79B | 0.25% | 74Outperform | |
| $58.29 | $64.87(11.29% Upside) | $4.04B | 0.38% | 70Neutral | |
| $124.94 | $155.49(24.45% Upside) | $3.86B | 0.07% | 70Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| XMMO | Invesco S&P MidCap Momentum ETF | 135.57 | 4.04 | 3.07% | |
| FMDE | Fidelity Enhanced Mid Cap ETF | 41.91 | 7.35 | 21.28% | |
| JHMM | John Hancock Multifactor Mid Cap ETF | 74.06 | 11.79 | 18.93% | |
| XMHQ | Invesco S&P MidCap Quality ETF | 120.09 | 21.45 | 21.74% | |
| DON | WisdomTree U.S. MidCap Dividend Fund | 58.29 | 9.52 | 19.53% | |
| IVOO | Vanguard S&P Mid-Cap 400 ETF | 124.94 | 19.71 | 18.73% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
